ArticleNature methods2022
MITI minimum information guidelines for highly multiplexed tissue images.
Abstract read
In one paragraph
Article in Nature methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Trustworthy Agentic AI in Bioinformatics: From Workflow Automation to Traceable and Validated Biological Inference.Biology · 2026Review
- Quantifying the spatiotemporal mechanical dynamics of engineered cardiac microbundles.PLoS computational biology · 2026Article
- Multiple human transgenes prolong survival of triple-carbohydrate knockout porcine kidney xenografts in nonhuman primates.Nature communications · 2026Article
- Review
- MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.PLoS computational biology · 2026Article
- Spatial proteomics: technical evolution and applications in cancer research.Frontiers in cell and developmental biology · 2026Review
- Spatial immune ecology of immunotherapy resistance in gastric and gastroesophageal junction adenocarcinoma.Frontiers in oncology · 2026Review
- Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Frontiers in cell and developmental biology · 2026Review
- Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).Journal for immunotherapy of cancer · 2025Article
- Making genomic data FAIR through effective Data Portals.Scientific data · 2025Article
- MIFA: Metadata, Incentives, Formats and Accessibility guidelines to improve the reuse of AI datasets for bioimage analysis.Nature methods · 2025Review
- Giotto Suite: a multiscale and technology-agnostic spatial multiomics analysis ecosystem.Nature methods · 2025Article
- Toward universal immunofluorescence normalization for multiplex tissue imaging with UniFORM.Cell reports methods · 2025Article
- Article
- Article
- Morphology-Aware Profiling of Highly Multiplexed Tissue Images using Variational Autoencoders.bioRxiv : the preprint server for biology · 2025Article
- Spatial determinants of tumor cell dedifferentiation and plasticity in primary cutaneous melanoma.bioRxiv : the preprint server for biology · 2025Article
- Enabling global image data sharing in the life sciences.Nature methods · 2025Review
- Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement.Nature methods · 2025Review
- Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Denis Schapiro *Laboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9391-5722
Clarence Yapp *Laboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1144-5710
Artem Sokolov *Laboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8056-0504
Sheila M ReynoldsInstitute for Systems Biology, Seattle, WA, USA.
Yu-An ChenLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Damir SudarQuantitative Imaging Systems LLC, Portland, OR, USA.ORCID http://orcid.org/0000-0002-2510-7272
Yubin XieProgram in Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeremy MuhlichLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0811-637X
Raquel Arias-CamisonLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Sarah ArenaLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Adam J TaylorSage Bionetworks, Seattle, WA, USA.
Milen NikolovSage Bionetworks, Seattle, WA, USA.
Madison TylerLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.
Jia-Ren LinLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4702-7705
Erik A BurlingameOregon Health and Science University, Portland, OR, USA.
Human Tumor Atlas Network
Young H ChangOregon Health and Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-8764-1959
Samouil L FarhiKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1359-4568
Vésteinn ThorssonInstitute for Systems Biology, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3498-2378
Nithya VenkatamohanDana-Farber Cancer Institute, Boston, MA, USA.
Julia L DrewesJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Dana Pe'erProgram in Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-9259-8817
David A GutmanSchool of Medicine, Emory University, Atlanta, GA, USA.
Markus D HerrmannDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7257-9205
Nils GehlenborgDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0327-8297
Peter BankheadEdinburgh Pathology, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0003-4851-8813
Joseph T RolandVanderbilt University School of Medicine, Nashville, TN, USA.
John M HerndonDepartment of Surgery, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-8378-9654
Michael P SnyderSchool of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0784-7987
Michael AngeloSchool of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1531-5067
Garry NolanSchool of Medicine, Stanford University, Stanford, CA, USA.
Jason R SwedlowDivision of Computational Biology and Centre for Gene Regulation and Expression, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0002-2198-1958
Nikolaus SchultzDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel T MerrickPathology, University of Colorado, Aurora, CO, USA.
Sarah A MazziliBoston University, Boston, MA, USA.
Ethan CeramiDana-Farber Cancer Institute, Boston, MA, USA.
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Sandro SantagataLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA. ssantagata@bics.bwh.harvard.edu.ORCID http://orcid.org/0000-0002-7528-9668
Peter K SorgerLaboratory of Systems Pharmacology, Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA. peter_sorger@hms.harvard.edu.ORCID http://orcid.org/0000-0002-3364-1838
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MINSTITUTIONAL TRAINING GRANT IN GENOME SCIENCET32HG000044 · NHGRI · STANFORD UNIVERSITY · PI MICHAEL P. SNYDER · 1995 to 2026
$32.2MHuman Tumor Atlas Network: Data Coordinating Center SupplementU24CA233243 · NCI · DANA-FARBER CANCER INST · PI ROBERT C GENTLEMAN, Nikolaus Schultz · 2018 to 2026
$29.1MThe Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE E. · 2018 to 2023
$13.7MData Analysis UnitU2CCA233285 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI TAN, KAI · 2018 to 2023
$13.2MTransition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain MetastasisU2CCA233284 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI IACOBUZIO-DONAHUE, CHRISTINE A, PE'ER, DANA · 2018 to 2022
$12.9MMolecular, Cellular and Tissue Characterization UnitU2CCA233291 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J., SHRUBSOLE, MARTHA J. · 2018 to 2023
$12.2MPreCancer Atlas of Familial Adenomatous PolyposisU2CCA233311 · NCI · STANFORD UNIVERSITY · PI FORD, JAMES M., SNYDER, MICHAEL P. · 2018 to 2023
$11.6MMolecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2018 to 2023
$11.4MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SHARPE, ARLENE H. · 2018 to 2022
$10.8MOmic and Multidimensional Spatial Atlas of Metastatic Breast CancerU2CCA233280 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOECKS, JEREMY · 2018 to 2023
$9.7MWASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTERU2CCA233303 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2018 to 2023
$9.7MNCI NIH HHS HHSN261201000031CNCI NIH HHS HHSN261201500001CNCI NIH HHS HHSN261201500001GNCI NIH HHS HHSN261201500001WNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS K08 CA230213NCI NIH HHS K08 CA237871NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA245499NCI NIH HHS R35 CA197570NCI NIH HHS R37 CA266185NCI NIH HHS U24 CA233243NCI NIH HHS U2C CA233195NCI NIH HHS U2C CA233238NCI NIH HHS U2C CA233254NCI NIH HHS U2C CA233262NCI NIH HHS U2C CA233280NCI NIH HHS U2C CA233284NCI NIH HHS U2C CA233285NCI NIH HHS U2C CA233291NCI NIH HHS U2C CA233303NCI NIH HHS U2C CA233311NCI NIH HHS U54 CA225088NHGRI NIH HHS T32 HG000044NIH HHS OT2 OD026677
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.